Tumor Immunology meets…Immunology: Modified cancer cells as professional APC for priming naïve tumor-specific CD4+ T cells

Documenti analoghi

• CIITA-driven MHC class II expressing tumor cells can efficiently prime naive CD4(+) TH cells in vivo and vaccinate the host against parental MHC-II-negative tumor cells
  di: Bou Nasser Eddine, Farah, et al.
  Pubblicazione: (2016)
• CIITA-Driven MHC Class II Expressing Tumor Cells as Antigen Presenting Cell Performers: Toward the Construction of an Optimal Anti-tumor Vaccine
  di: Roberto S. Accolla, et al.
  Pubblicazione: (2019-07-01)
• CIITA-Driven MHC Class II Expressing Tumor Cells as Antigen Presenting Cell Performers: Toward the Construction of an Optimal Anti-tumor Vaccine
  di: Accolla, Roberto S., et al.
  Pubblicazione: (2019)
• CIITA-related block of HLA class II expression, upregulation of HLA class I, and heterogeneous expression of immune checkpoints in hepatocarcinomas: implications for new therapeutic approaches
  di: Ramia, Elise, et al.
  Pubblicazione: (2018)
• Boosting the MHC Class II-Restricted Tumor Antigen Presentation to CD4+ T Helper Cells: A Critical Issue for Triggering Protective Immunity and Re-Orienting the Tumor Microenvironment Toward an Anti-Tumor State
  di: Accolla, Roberto S., et al.
  Pubblicazione: (2014)